Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $6,015,296.00 in Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CEO Herriot Tabuteau sold 32,410 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $185.60, for a total value of $6,015,296.00. Following the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at $1,341,702.40. This represents a 81.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Herriot Tabuteau also recently made the following trade(s):

• On Monday, January 5th, Herriot Tabuteau sold 78,703 shares of Axsome Therapeutics stock. The shares were sold at an average price of $171.28, for a total transaction of $13,480,249.84.
• On Tuesday, January 6th, Herriot Tabuteau sold 29,450 shares of Axsome Therapeutics stock. The shares were sold at an average price of $172.33, for a total transaction of $5,075,118.50.
• On Wednesday, January 7th, Herriot Tabuteau sold 31,261 shares of Axsome Therapeutics stock. The stock was sold at an average price of $170.38, for a total value of $5,326,249.18.
• On Thursday, December 4th, Herriot Tabuteau sold 10,558 shares of Axsome Therapeutics stock. The stock was sold at an average price of $148.18, for a total value of $1,564,484.44.
• On Tuesday, December 2nd, Herriot Tabuteau sold 49,252 shares of Axsome Therapeutics stock. The shares were sold at an average price of $144.59, for a total value of $7,121,346.68.
• On Wednesday, December 3rd, Herriot Tabuteau sold 20,163 shares of Axsome Therapeutics stock. The stock was sold at an average price of $146.94, for a total transaction of $2,962,751.22.
• On Tuesday, November 4th, Herriot Tabuteau sold 50,459 shares of Axsome Therapeutics stock. The shares were sold at an average price of $133.79, for a total transaction of $6,750,909.61.
• On Wednesday, November 5th, Herriot Tabuteau sold 21,775 shares of Axsome Therapeutics stock. The stock was sold at an average price of $134.49, for a total transaction of $2,928,519.75.

Axsome Therapeutics Stock Up 0.9%

AXSM traded up $1.63 on Monday, hitting $185.88. The company had a trading volume of 581,077 shares, compared to its average volume of 758,020. The stock has a market capitalization of $9.37 billion, a price-to-earnings ratio of -39.80, a P/E/G ratio of 11.89 and a beta of 0.44. The stock has a fifty day moving average price of $163.29 and a 200-day moving average price of $136.05. Axsome Therapeutics, Inc. has a 12-month low of $86.99 and a 12-month high of $191.50. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.50 and a current ratio of 1.57.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The firm had revenue of $170.99 million during the quarter, compared to the consensus estimate of $162.96 million. The business’s quarterly revenue was up 63.2% on a year-over-year basis. Analysts predict that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AXSM has been the topic of several research analyst reports. Leerink Partners boosted their target price on shares of Axsome Therapeutics from $150.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 28th. Mizuho set a $217.00 target price on Axsome Therapeutics in a research report on Wednesday, December 31st. Wells Fargo & Company lifted their price objective on Axsome Therapeutics from $157.00 to $193.00 and gave the company an “overweight” rating in a research note on Tuesday, January 13th. UBS Group lifted their target price on shares of Axsome Therapeutics from $163.00 to $248.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Finally, TD Cowen restated a “buy” rating on shares of Axsome Therapeutics in a research report on Thursday. Nineteen research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Axsome Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $206.22.

Institutional Investors Weigh In On Axsome Therapeutics

A number of hedge funds have recently modified their holdings of AXSM. Allworth Financial LP raised its stake in shares of Axsome Therapeutics by 6.6% in the third quarter. Allworth Financial LP now owns 1,442 shares of the company’s stock valued at $175,000 after acquiring an additional 89 shares in the last quarter. Moors & Cabot Inc. grew its holdings in Axsome Therapeutics by 4.5% during the 2nd quarter. Moors & Cabot Inc. now owns 2,330 shares of the company’s stock worth $243,000 after acquiring an additional 100 shares in the last quarter. Meridian Wealth Management LLC raised its holdings in shares of Axsome Therapeutics by 0.5% in the 3rd quarter. Meridian Wealth Management LLC now owns 22,124 shares of the company’s stock valued at $2,687,000 after purchasing an additional 103 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Axsome Therapeutics by 65.4% during the fourth quarter. GAMMA Investing LLC now owns 268 shares of the company’s stock worth $49,000 after purchasing an additional 106 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Axsome Therapeutics by 1.1% in the second quarter. China Universal Asset Management Co. Ltd. now owns 9,889 shares of the company’s stock valued at $1,032,000 after buying an additional 107 shares during the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.